Guggenheim raised the firm’s price target on Axsome Therapeutics to $125 from $110 and keeps a Buy rating on the shares. Auvelity is outperforming and the firm expects Auvelity to continue to outperform Street expectation, adding that it has a positive view on the company’s ADA and narcolepsy opportunities.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AXSM:
- Axsome Therapeutics Inc. Reported Earnings. Did it Beat Estimates?
- Axsome Therapeutics Updates Corporate Presentation Online
- Axsome Therapeutics reports Q4 EPS ($2.08), consensus ($1.17)
- Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Axsome Therapeutics price target raised to $112 from $90 at Mizuho
